Evidence rather than costs must guide use of the implantable cardioverter defibrillator

Details

Serval ID
serval:BIB_15E189632377
Type
Article: article from journal or magazin.
Publication sub-type
Review (review): journal as complete as possible of one specific subject, written based on exhaustive analyses from published work.
Collection
Publications
Institution
Title
Evidence rather than costs must guide use of the implantable cardioverter defibrillator
Journal
American Journal of Cardiology
Author(s)
Delacretaz  E., Schlaepfer  J., Metzger  J., Fromer  M., Kappenberger  L.
ISSN
0002-9149 (Print)
Publication state
Published
Issued date
11/2000
Volume
86
Number
9A
Pages
52K-57K
Notes
Journal Article
Review --- Old month value: Nov 2
Abstract
Randomized controlled trials have shown superior survival rates with implantable cardioverter defibrillators (ICDs) compared with antiarrhythmic drugs in survivors of cardiac arrest and life-threatening ventricular tachyarrhythmias, as well as in high-risk patients with ischemic heart disease and inducible ventricular tachycardia (VT). Current defibrillators are small and implanted with techniques similar to standard pacemakers. They provide high-energy shocks for ventricular fibrillation (VF) and rapid VT, antitachycardia pacing for monomorphic VT, and antibradycardia pacing. Limited evidence suggests that ICD therapy is cost-effective when compared with other widely accepted treatments. The use of ICDs is likely to continue to expand in the future. Ongoing clinical trials will define further prophylactic indications of the ICD and clarify its cost-effectiveness ratio in different clinical settings.
Keywords
Cost-Benefit Analysis Death, Sudden, Cardiac/etiology/*prevention & control *Defibrillators, Implantable/economics Electric Countershock/economics/*instrumentation Humans Patient Selection Tachycardia, Ventricular/*therapy Ventricular Fibrillation/*therapy
Pubmed
Web of science
Create date
28/01/2008 10:09
Last modification date
20/08/2019 12:45
Usage data